World's Top Urological Specialists Meet In San Diego To Hear Latest Scientific Information On Genitourinary Disease

May 29, 1998

More than 1,800 original research studies aimed at preventing, diagnosing, and treating adult and childhood diseases of the kidney, urethra, and genitals, plus dozens of state-of-the-art educational presentations, will highlight the 93rd Annual Meeting of the American Urological Association at the San Diego Convention Center, San Diego, California, May 30 - June 4, 1998.

As part of the expected overall attendance of 14,000, more than 7,500 urologists, other physicians, biomedical researchers, and healthcare professionals will participate in the world's largest and most comprehensive urologic educational and scientific forum. These individuals will attend plenary sessions, lectures, panel discussions, point/counterpoint debates, poster and podium sessions, video presentations, and instructional courses. General topic areas to be featured include prostate cancer, benign prostatic hyperplasia (BPH) or enlarged prostate, erectile dysfunction (impotence), urinary tract infection, urinary incontinence, kidney stone disease, infertility, bladder cancer, and kidney cancer.

Some of the important original research findings to be presented at the meeting include:In addition to multiple presentations based on original research, meeting registrants will hear dozens of state-of-the-art lectures, special seminars, and panel discussions on a variety of important urological topics. A feature of the meeting involves Point/Counterpoint debates on special topics by two experts with opposing urologic views.

Following are some convention highlights:

Sunday, May 31 Monday, June 1 Tuesday, June 2 Wednesday, June 3 Thursday, June 4

The final morning will be devoted to a series of "Take Home" messages by recognized authorities. These experts will summarize the total material presented during the meeting in various topic areas focusing on issues critical to the practicing urologist. Highlights include:

American Urological Association

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to